Revumenib + intensive chemotherapy for newly diagnosed acute myeloid leukemia harboring genetic alterations in KMT2A, NPM1, or NUP98: updated phase 1 results from SNDX-5613-0708

Poster Presentation | Jun 12, 2026

Author

Aldoss I, et al.

Congress

European Hematology Association Annual Congress 2026

Stockholm, Sweden | June 11 – 14, 2026